- 1 Title: Protocol for a prospective, hospital-based registry of pregnant women with SARS-CoV-2
- 2 infection in India: PregCovid Registry study
- 3 Authors
- 4 Rahul K Gajbhiye, MBBS, PhD 1* ,
- 5 Niraj N Mahajan, MD^2 ,
- 6 Rakesh Waghmare, $MD^{3,4}$,
- 7 Suchitra Surve, MBBS, DCH¹,
- 8 Prashant Howal, MD^4 ,
- 9 Aishwarya Bhurke, MSc^1 ,
- 10 Merlin Pious, MSc^1 ,
- 11 Deepak N Modi, PhD^5 ,
- 12 Smita D Mahale, $PhD^{6#}$

13 Author affiliations

- ¹Clinical Research Lab, ICMR-National Institute for Research in Reproductive Health, Mumbai,
- 15 India
- ²Department of Obstetrics & Gynecology, Topiwala National Medical College & BYL Nair
- 17 Charitable Hospital, Mumbai India
- ³Medical Education and Drugs Department, Government of Maharashtra, India
- ⁴Department of Community Medicine, Grant Government Medical College, and Sir J. J. Group
- 20 of Hospitals, Mumbai, India
- ²¹ ³Molecular and Cellular Biology Laboratory, ICMR-National Institute for Research in
- 22 Reproductive Health, J M Street, Parel, Mumbai
- ²³ ⁶Structural Biology Department, ICMR-National Institute for Research in Reproductive Health,

- 24 J M Street, Parel, Mumbai, India
- 25 # superannuated
- 26 **Corresponding Author:**
- 27 Dr. Rahul Gajbhiye (0000-0003-3864-1818)
- 28 Scientist D & DBT Wellcome India Alliance
- 29 Clinical & Public Health Intermediate Fellow,
- 30 Clinical Research Lab,
- 31 ICMR-National Institute for Research in Reproductive Health,
- 32 Parel, Mumbai, 400012, INDIA
- 33 Telephone: +91 22 24192036

34 Email: gajbhiyer@nirrh.res.in

35 ABSTRACT

Introduction: Pregnant women are at increased risk of contracting coronavirus disease 2019 (COVID-19) due to several factors and therefore require special attention. However, the consequences of the COVID-19 pandemic on pregnant women and their newborns remain uncharted. The PregCovid registry aims to document the impact of SARS-CoV-2 infection on pregnant, post-partum women and their newborns. The aim of the registry is also to determine mother-to-child transmission of SARS-CoV-2 infection in India.

42 **Methods and analysis:** PregCovid is a hospital-based registry for capturing information of 43 pregnant, post-partum women with COVID-19 and their newborns in India. Medical case

44 records of pregnant and post-partum women with laboratory-confirmed diagnoses of COVID-19 45 will be captured in real-time using an online electronic patient record (EPR) software. The frequency of each symptom will be calculated. The laboratory data will be analyzed for 46 47 calculating the frequency of laboratory parameters consistently higher in women with COVID-19. The adverse pregnancy and neonatal outcomes will be analyzed and their frequency will be 48 49 calculated. Response to treatment will be analyzed for frequency calculation (number of women 50 treated with different treatment regimens). The mother-to-child transmission data will be analyzed from the RT-PCR and/ antibody data of neonatal and maternal samples tested wherever 51 52 the information is available. The registry data will be crucial for developing strategies for reducing the adverse impact of COVID-19 on pregnant women and their new-born. 53

Ethics and dissemination: The study is approved by the Institutional Ethics Committee of ICMR-National Institute for Research in Reproductive Health (#55/2020), BYL Nair Hospital, Mumbai, India (# 63/2020); and all the 18 participating study sites under Medical Education and Drugs Department of Government of Maharashtra. The Institutional Ethics Committees granted a waiver of consent as the data is collected from the medical case records.

59 Trial registration number: CTRI/2020/05/025423

Keywords: COVID-19, Coronaviruses, New-born, Pregnancy, Registry, Viruses, Vertical
 transmission

62 Article summary

63 Strengths and limitations of this study

• The PregCovid registry is a hospital-based registry at dedicated COVID-19 hospitals in India. The registry will help to identify new epidemiological, clinical characteristics, obstetrics outcomes associated with pregnant women and/post-partum women with

67		COVID-19 in India. The study will also generate information on clinical presentations
68		and outcomes of neonatal born to mothers with COVID-19 in India.
69	•	PregCovid registry will provide evidence of mother to child transmission of SARS-CoV-
70		2 infection in Indian women
71	•	The evidence on unusual presentations of COVID-19 in pregnant and post-partum
72		women will be generated.
73	•	The follow-up of participants is only till the discharge from the hospital. Long-term
74		follow-up is not included in the study.
75		

76 Introduction

77 Coronavirus disease 2019 (COVID-19) has emerged as a public health emergency with more than 103 million confirmed cases of COVID-19, including 2.3 million deaths, worldwide as [1]. 78 79 Several variants of SARS-CoV-2 are now emerging [2] however, it is still unknown whether 80 they have any clinical impact on pregnant women. Several International and National agencies are actively engaged to address the impact of the COVID-19 pandemic. Previously, members of 81 the coronavirus family such as severe acute respiratory syndrome coronavirus (SARS-Co-V) and 82 Middle East Respiratory Syndrome (MERS-CoV) were reported to be associated with severe 83 84 complications during pregnancy like miscarriage, fetal growth restriction, preterm birth, and 85 maternal deaths [3]. In general, pregnant women are a vulnerable population and need special 86 attention. Pregnant women are particularly susceptible to respiratory pathogens and severe pneumonia, due to various factors such as physiologic changes in the immune and 87 88 cardiopulmonary systems (e.g. diaphragm elevation, increased oxygen consumption, and edema 89 of respiratory tract mucosa) which make them at risk of hypoxia [4]. Since the initial period of 90 reporting case reports or case series on pregnant women with COVID-19 from China, now there 91 are several studies published from different geographical regions. Initial studies mainly from China reported that clinical presentation of pregnant women with COVID-19 was comparable to 92 non-pregnant cases and there was no risk of mother to child transmission of Severe acute 93 94 respiratory syndrome coronavirus 2 (SARS-CoV-2) infection [5]. However, subsequently, 95 studies were demonstrating the adverse impact of COVID-19 on both maternal and newborn health [4,6–9]. Evidence is gathering which suggests that there might be population biases in the 96 susceptibility of COVID-19. Analysis of 427 pregnant women of the UK registry revealed that 97 there might be racial differences in the severity of presentation and outcomes [7]. Also, a higher 98

99 incidence of maternal death due to COVID-19 is reported in some countries as compared to 100 China or Europe [10]. Similarly, in the United States of America (USA), ethnic disparities in 101 incidence and outcomes are also observed in non-pregnant populations with COVID-19, notably 102 in the USA [11]. Factors such as social behavior, health-seeking behavior, comorbidities, and unknown genetic influences could be possible causes of differences in presentation and outcomes 103 of COVID-19. This highlights a need for population-specific data of pregnant women, to gain an 104 105 insight into social-epidemiological and clinical determinants of outcomes in COVID-19. 106 Currently, in India, the number of COVID-19 cases is on the rise. The Ministry of Health and Family Welfare (MoHFW), Government of India, reported 1,04,80,455 total confirmed cases 107 with 1,54,703 deaths as of 4th February 2021 [12]. Out of these, Maharashtra state contributed 108 19,43,335 cases with 51,169 deaths due to COVID-19 [12]. COVID-19 affected Indian states 109 110 including Maharashtra which need special attention in planning the strategies for combating 111 COVID-19, especially in the vulnerable population such as pregnant women. Our preliminary observations suggest that nearly 12% of pregnant women in Maharashtra State have SARS-CoV-112 113 2 infection and about 10% of these are symptomatic, highlighting the emergency nature of the situation [13]. Currently, there is no epidemiological, demographic, and clinical information on 114 pregnant women with COVID-19 in India. Additionally, health outcomes of neonates born to 115 116 COVID-19 mothers have not been documented in the Indian population. To address the knowledge gaps, ICMR-National Institute for Research in Reproductive Health 117

(NIRRH) has initiated a hospital-based pregnancy registry to capture socio-demographic, clinical
 presentations, treatment outcomes, obstetric and neonatal outcomes in Indian women with
 COVID-19. Herein, we describe the protocol and the characteristics of this registry.

122 Aim of PregCovid study

- 123 The following research questions will be addressed:
- What are the clinical characteristics of pregnant and post-partum women who are
 diagnosed with SARS- CoV-2 infection?
- 126 2. What are the pregnancy outcomes in Indian women with SARS-CoV-2 infection?
- 127 3. How does the treatment of SARS- CoV-2 infection in pregnancy influence the outcomes128 for mother and infant?
- 4. Are there any ethnic or socioeconomic determinants of clinical presentations andoutcomes of COVID-19 in pregnant women?

131 **Objectives**

- 132 The objectives of the study are: a) To understand the socio-demographic, clinical presentations,
- reproductive characteristics of pregnant and post-partum women diagnosed with SARS-CoV-2
- 134 infection b) To determine the pregnancy and fetal outcomes in women with SARS-CoV-2
- infection and study the effect of treatment on pregnancy outcomes c) To evaluate the proportion
- 136 of maternal to the fetal transmission of SARS-CoV-2 infection in pregnancy.

137 Materials and methods

138 The PregCovid registry is a prospective, hospital-based study designed to capture hospital data of 139 pregnant and post-partum women with COVID-19 and their newborns.

140 Identification of study sites for data capturing

141 Since Maharashtra is a hotspot region for COVID-19, it was decided initially to launch the 142 registry to capture the data in the state. Towards that, the Medical Education and Drugs 143 Department (MEDD) Government of Maharashtra and Municipal Corporation of Greater

144 Mumbai (MCGM) were consulted, and primary data on COVID-19 and pregnant women were 145 collected by a rapid survey.

146 **Data collection instrument**

An *a priori* requirement of the registry was the development of the case record form. Towards this RG and DM carried out a situational analysis of the current evidence on the effectiveness and outcomes of COVID-19 on pregnant women [14]. Based on the outcomes of the systematic review of the baseline data of more than 400 women from different parts of the world and also reviewing the USA registry PRIORITY: Pregnancy Coronavirus Outcomes Registry [15], we shortlisted the key parameters about which the information should be collected.

In the next step, the case record form was independently reviewed by a team of gynecologists 153 and pediatricians. Their inputs were recorded and the case record form was modified by a 154 155 consensus. The modified case record form was circulated to the Investigators (Professor & Head, 156 Obstetrics and Gynecology Departments, and Professor & Head Pediatrics/Neonatology 157 Department) of the PregCovid Registry Network for further feedback and its feasibility as they 158 have experience of treating the COVID-19 cases. RG coordinated with Investigators of the PregCovid Registry Network Hospitals for pilot testing of the case record form. Based on the 159 feasibility and pilot testing, the case record form was modified and finalized by the consensus of 160 investigators (Table 1). 161

162 **Tools for real-time data capture**

To capture the real-time data, an online electronic patient record (EPR) software was developed by an outsourced team of experts. The developed software was first tested using dummy data by a team of obstetricians and pediatricians from the participating study sites. The time for data entry was recorded for obstetrics and pediatrics sections. Based on the inputs received from the

user team, the software was modified and pilot testing was carried out before the actual start ofthe data entered into the software.

169 Approval from Institutional Review Boards (IRB)

170 The study is approved by the Institutional Ethics Committee of ICMR-National Institute for

171 Research in Reproductive Health (#55/2020), BYL Nair Hospital, Mumbai, India (# 63/2020);

and all the 18 participating study sites under Medical Education and Drugs Department of

- 173 Government of Maharashtra. The Institutional Ethics Committees granted a waiver of consent as
- the data is collected from the medical case records.

175 **CTRI Registration**

The study is registered with the Clinical Trials Registry, India (CTRI) and the registration
number is CTRI/2020/05/025423.

178 Characteristics of the PregCovid registry network and requirements of additional 179 participating centers

The overall flow of the study protocol is outlined in Figure 1. The registry is presently initiated with 19 participating centers; it is open for all public and private COVID-19 hospitals all over India. A dedicated PregCovid portal for data entry (<u>http://app.pregcovid.com/login</u>) is developed along with a website for giving information about the registry for prospective collaborators, publications, and any breakthrough information related to the registry (<u>https://pregcovid.com/</u>). BYL Nair Hospital, Mumbai, a dedicated COVID-19 hospital was the first study site of PregCovid registry [16].

187 Maharashtra State is the second most populous state in India with 112,374,333 of which male 188 and female are 58,243,056 and 54,131,277 respectively [17]. The first case of COVID-19 in 189 Maharashtra State was detected in Pune on 9th March 2020 and since then Maharashtra is

harboring around 30% of the total cases of COVID-19 burden in India [18]. To respond to this
public health emergency, phase 1 of the implementation of the registry will be carried out
through the 19 participating centers within Maharashtra.

The registry is open to others who wish to become a part of this network. The approaching centers must contact the Coordinator or the Principal Investigator of the registry at ICMR-NIRRH. They will need to obtain approval from their Institutional Ethics Committee and sign a Memorandum of Agreement with ICMR-NIRRH, Mumbai. For further details, the centers can visit the PregCovid website (https://pregcovid.com/for-covid19-hospitals/).

198 **Timelines**

The registry will collect anonymized real-time data of pregnant women diagnosed with COVID-19 and admitted until May 2022. The date is extendable depending on the duration of the pandemic. Interim analysis may be conducted at the discretion of the investigators in consultation with other stakeholders. The final analysis will be done after collecting all the data.

203 **Study instruments**

The registry is implemented through an app-based Electronic Patient Record (EPR) which is shared with participating centers and the site Principal Investigator (PI) will be responsible for data entry. Software is developed for online real-time data entry. The data will be entered online in the EPR from the original medical records of pregnant and/post-partum women with confirmed COVID-19 infection admitted in COVID-19 hospitals.

209 Case record form

The case record form is designed to include socio-demographic, epidemiological, clinical presentations, laboratory investigations, past medical and surgical history, current pregnancy details, pregnancy complications, treatment details, and outcomes. New-born data collection tool

includes date and time of delivery, mode of delivery, birth weight, sex of infant, whether
livebirth/stillbirth, diagnosis with COVID-19 infection (if any), morbidity, and mortality data
(Table 1).

216 Training for data entry, monitoring, and quality control

The site PIs and their team will be provided online training for data entry, quality control measures, and accuracy. A training manual and a video of detailed instructions on the use of the software will be provided to all participating study sites. The site PI will ensure that the data is entered in a near real-time manner. The site PIs will monitor the entry of individual data and ensure its accuracy. The team at NIRRH will periodically review the data entered for gaps and discrepancies.

223 Data management, Protection of Privacy & Confidentiality

No information will be collected related to the identity of the study participants. The names of 224 225 the COVID-19 patients will not be entered into any of the documents. None of the COVID-19 226 patient's details revealing their identity will be used in any reports and publications arising from 227 this study. The information as per the case record form will be captured electronically in a 228 central database created, maintained, and regularly updated at ICMR-NIRRH. Data entry and data access will be independently controlled and held behind secure firewalls. Data collected 229 from different study sites will be kept separately and only specific individuals within a research 230 team will be able to access and edit the data. The quality of the electronic data will be regularly 231 232 monitored by the PI and research team at ICMR-NIRRH.

233 Statistical analysis

The frequency of each symptom will be calculated. The laboratory data will be analyzed for calculating the frequency of laboratory parameters consistently higher in women with COVID-

19. The adverse pregnancy and neonatal outcomes will be analyzed and their frequency will be calculated. Response to treatment will be analyzed for frequency calculation (number of women treated with different treatment regimens). The mother-to-child transmission data will be analyzed from the RT-PCR and/ antibody data of neonatal and maternal samples tested wherever the information is available. Data pooling and statistical analysis will be carried out using MS Excel and SPSS version 26 (SPSS South Asia Pvt. Ltd., Bangalore, India).

242 **Patient and public involvement**

No patients or public were involved in the study design, conduct or reporting of our analysis.

244 **Discussion**

To the best of our knowledge, this is the first registry on pregnant women with COVID-19 in 245 246 India for capturing data on clinical presentation, obstetrics and neonatal outcomes, response to treatment, and mother to child transmission of SARS-CoV-2 infection. While the initial focus is 247 on Maharashtra, as the pandemic unfolds, we anticipate having membership from different states 248 249 representative of the Indian population. In its present form, it is geared to generate data of the 250 worst affected state in India in a very systematic manner and its interim analysis would help 251 other states to plan their strategies well in advance to manage pregnant women infected with 252 SARS-CoV-2.

The study will also generate information on the ethnic and socio-demographic determinants of the clinical presentation, and outcomes of pregnant women with COVID-19. Together, this data will aid in planning the strategies to handle the epidemic of COVID-19 and pregnancy. This data is extremely important to develop rational management strategies for protecting pregnant women against possible adverse effects of COVID-19. This information will be also of

258 importance not just for COVID-19 but also provide a broad framework to deal with an entire 259 group of coronaviruses that lead to common respiratory infections in general.

260 The preliminary findings of the registry data are useful for improved management of pregnancy 261 with COVID-19. ICMR recommends universal testing of pregnant women in India. Accordingly, women residing in clusters/containment areas or large migration gatherings/evacuees centers 262 263 from hotspot districts in India and presenting in labor or likely to deliver in the next 5 days were 264 recommended to be screened for SARS-CoV-2 [19]. We observed a 12 % prevalence of SARS-265 CoV-2 in pregnant women with the presence of one symptomatic to every nine asymptomatic 266 pregnant women [13]. These findings of the universal testing strategy of pregnant women are 267 useful for planning strategies to prevent the spread of the virus to newborns, healthcare workers, and others in the community. The study also highlights that pregnant women should be paying 268 269 special attention to their health. The significance of detecting asymptomatic pregnant women is 270 useful for ensuring safe obstetric and neonatal services and assessing the burden of COVID-19 in 271 the region to plan strategies on strengthening or relaxing mass physical distancing measures.

Detection of dengue and malaria coinfection with COVID-19 in pregnant women is useful for formulating the strategies for pregnant women living in malaria and dengue-endemic zones [20]. Considering the COVID-19 reaching the tribal and rural parts of India, both public and private healthcare systems should be strengthened for diagnosis and appropriate management of coinfections. Documentation of post-partum psychosis in mothers with COVID-19 [21] is useful for creating awareness and providing appropriate mental health care for pregnant and postpartum women with COVID-19.

Globally, there are several National, Regional and International registries being established for
pregnant women with COVID-19[22]. The objectives and the protocol of the PregCovid registry

are at par with these international registries and will open up an opportunity at the international level for data comparison and assimilation. Eventually, collaborations with an international consortium with global experts having experience in managing COVID-19 pregnant women would be useful for developing a global strategy on COVID-19 in pregnancy.

285 **Publication plan**

- 286 Publications will be submitted to international peer-reviewed journals on findings emerged from
- the data of the PregCovid study. Press releases and articles for lay audiences will also be
- 288 prepared for important findings.

289 Abbreviations

- 290 COVID-19: Coronavirus disease 2019
- 291 CTRI: Clinical Trial Registry of India
- 292 EPR : Electronic patient record
- 293 IRB : Institutional Review Boards
- 294 MEDD : Medical Education and Drugs Department
- 295 MCGM : Municipal Corporation of Greater Mumbai
- 296 MERS-CoV : Middle East Respiratory Syndrome
- 297 MoHFW: Ministry of Health and family Welfare
- 298 PRIORITY: Pregnancy Coronavirus Outcomes Registry
- 299 SARS-CoV : Severe acute respiratory syndrome coronavirus
- 300 SARS-CoV-2 : Severe acute respiratory syndrome coronavirus 2
- 301 Acknowledgments

302 The authors sincerely acknowledge the support of the Director-General, Indian Council of 303 Medical Research. Secretary, Medical Education, and Drugs Department; Director, Medical Education, and Drugs Department, Maharashtra; Dean, TNMC, Mumbai & BYL Nair Hospital; 304 305 are acknowledged. Dr. Vandana Bansal, Dr. Dipti Tandon, Dr. Anushree Patil, Dr. Sudha Rao, Dr. Shakuntala Prabhu, Dr. Pooja Bandekar are sincerely acknowledged. All the Site 306 Investigators and faculty, residents, interns working in the Departments of Obstetrics & 307 Gynecology; Pediatrics and Neonatology of the network of the National Registry of Pregnant 308 women with COVID-19 in India are sincerely acknowledged (PregCovid Registry, 309 310 CTRI/2020/05/025423).

311 Ethics approval and consent to participate

The study is approved by the Institutional Ethics Committee of ICMR-National Institute for Research in Reproductive Health (#55/2020), BYL Nair Hospital, Mumbai, India (# 63/2020); and all the 18 participating study sites under Medical Education and Drugs Department of Government of Maharashtra. The Institutional Ethics Committees granted a waiver of consent as the data is collected from the medical case records.

317 **Data availability**

318 Data sharing is not applicable as no datasets were generated and/or analyzed for this study.

319 Funding

PregCovid registry is supported by an intramural grant of ICMR-NIRRH (ICMRNIRRH/RA/965/09/2020). Rahul K Gajbhiye is an awardee of the DBT Wellcome India alliance
clinical and public health intermediate fellowship (Grant no. IA/CPHI/18/1/503933).

323 Authors' contributions

- 324 Concept and design: RG
- 325 Development and validation of data collection instrument: RG, NM, RW, SS,
- 326 Pilot testing & validation of software: NM, AB, MP, RW, PH
- 327 Development of Training manual, online training: NM, AB, MP, RG, RW
- 328 Drafting of the manuscript: RG, NM, DM, SM
- 329 Critical revision of the manuscript for important intellectual content: All authors
- Administrative and technical support: RG, RW, NM, SM
- 331 Competing Interest
- 332 There are no competing interests for any author.

333 **References**

334 Coronavirus disease (COVID-19) - World Health Organization. 1 335 https://www.who.int/emergencies/diseases/novel-coronavirus-2019 (accessed 4 Feb 2021). 336 2 Burki T. Understanding variants of SARS-CoV-2. The Lancet 2021;397:462. doi:10.1016/S0140-6736(21)00298-1 337 Diriba K, Awulachew E, Getu E. The effect of coronavirus infection (SARS-CoV-2, MERS-338 3 339 CoV, and SARS-CoV) during pregnancy and the possibility of vertical maternal-fetal transmission: a systematic review and meta-analysis. Eur J Med Res 2020;25:39-39. 340 doi:10.1186/s40001-020-00439-w 341 Yan J, Guo J, Fan C, et al. Coronavirus disease 2019 (COVID-19) in pregnant women: A 342 4 343 report based on 116 cases. American Journal of Obstetrics & Gynecology 2020;0. doi:10.1016/j.ajog.2020.04.014 344 Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission 345 5 346 potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. The Lancet 2020;395:809-15. doi:10.1016/S0140-6736(20)30360-3 347 348 6 Chen L, Li Q, Zheng D, et al. Clinical Characteristics of Pregnant Women with Covid-19 in 349 Wuhan, China. New England Journal of Medicine 2020;0:null. doi:10.1056/NEJMc2009226 Knight M, Bunch K, Vousden N, et al. Characteristics and outcomes of pregnant women 350 7 351 admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study. BMJ 2020;369:m2107. doi:10.1136/bmj.m2107 352 Kayem G, Lecarpentier E, Deruelle P, et al. A snapshot of the Covid-19 pandemic among 353 8 pregnant women in France. J Gynecol Obstet Hum Reprod 2020;49:101826. 354 355 doi:10.1016/j.jogoh.2020.101826 Ellington S, Strid P, Tong VT, et al. Characteristics of Women of Reproductive Age with 356 9 Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status — United States, 357 January 22–June 7, 2020. MMWR Morb Mortal Wkly Rep 2020;69:769–75. 358 359 doi:10.15585/mmwr.mm6925a1 10 Takemoto MLS, Menezes M de O, Andreucci CB, et al. The tragedy of COVID-19 in Brazil: 360 124 maternal deaths and counting. Int J Gynaecol Obstet Published Online First: 9 July 361 2020. doi:10.1002/ijgo.13300 362 363 11 Onwuzurike C, Diouf K, Meadows AR, et al. Racial and ethnic disparities in severity of COVID-19 disease in pregnancy in the United States. Int J Gynaecol Obstet Published 364 Online First: 31 July 2020. doi:10.1002/ijgo.13333 365 12 MoHFW | Home. https://www.mohfw.gov.in/ (accessed 4 Feb 2021). 366

367 368 369	13	Waghmare R, Gajbhiye R, Mahajan N, <i>et al.</i> Universal screening identifies asymptomatic carriers of SARS-CoV-2 among pregnant women in India. <i>European Journal of Obstetrics and Gynecology and Reproductive Biology</i> doi:10.1016/j.ejogrb.2020.09.030
370 371 372	14	Gajbhiye R, Modi D, Mahale S. Pregnancy outcomes, Newborn complications and Maternal- Fetal Transmission of SARS-CoV-2 in women with COVID-19: A systematic review. <i>medRxiv</i> 2020;:2020.04.11.20062356. doi:10.1101/2020.04.11.20062356
373 374	15	PRIORITY: Pregnancy Coronavirus Outcomes Registry. PRIORITY Study. https://priority.ucsf.edu/home (accessed 28 Aug 2020).
375 376 377 378 379	16	Mahajan NN, Pednekar R, Patil SR, <i>et al.</i> Preparedness, administrative challenges for establishing obstetric services, and experience of delivering over 400 women at a tertiary care COVID 19 hospital in India. International Journal of Gynecology & Obstetrics. 2020.https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1002/ijgo.13338 (accessed 25 Aug 2020).
380 381 382	17	Census of India : Maharashtra Vol1. https://censusindia.gov.in/2011census/maps/atlas/Maharashtra1.html (accessed 28 Aug 2020).
383 384 385	18	MEDD MARATHI 28 AUGUST 2020 REPORT.pdf. Google Docs. https://drive.google.com/file/d/11C5mgcrmFO8cLaCy4NY1DtUCbGupCGNL/view?usp=sha ring&usp=embed_facebook (accessed 28 Aug 2020).
386 387 388 389 390	19	INDIAN COUNCIL OF MEDICAL RESEARCH, DEPARTMENT OF HEALTH RESEARCH. Strategy for COVID19 testing for pregnant women in India (Version 1, dated 20/04/2020). 2020.https://www.icmr.gov.in/pdf/covid/strategy/COVID19_Testing_Strategy_for_Pregnant _Women.pdf
391 392 393 394	20	Mahajan NN, Kesarwani SN, Shinde SS, <i>et al.</i> Co infection of malaria and dengue in pregnant women with SARS CoV 2. International Journal of Gynecology & Obstetrics. 2020.https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1002/ijgo.13415 (accessed 19 Oct 2020).
395 396 397	21	Subramanyam AA, Nachane HB, Mahajan NN, <i>et al.</i> Postpartum psychosis in mothers with SARS-CoV-2 infection: A case series from India. <i>Asian Journal of Psychiatry</i> 2020;:102406. doi:10.1016/j.ajp.2020.102406
398 399	22	Covid-19 & pregnancy – registries. Ripe-tomato.org. 2020.https://ripe- tomato.org/2020/04/19/covid-19-pregnancy-registries/ (accessed 23 Jul 2020).
400		

402

Table 1: Maternal and New-born information concerning different parameters captured by Electronic Patient Record for PregCovid registry

Maternal Information	Parameters
Socio-Demographic and Epidemiological data	Age, Religion, Occupation, Education, Financial status, Residential area (Red zone, Orange, Green)
Medical History	Anemia, Diabetes Mellitus, Chronic Hypertension, Blood disorders, Chronic obstructive disease, Asthma, Tuberculosis, Cardiac disorders, Psychiatric disorders, Thyroid disorders, Kidney disorder, rheumatoid arthritis, malignancy, Immunocompromised state, Previous surgical history, H/o contact in the community, exposure while caring for COVID-19 patient and foreign travel
Obstetric History	Gestational Age, and conception history, Gravida, Parity, Mode of delivery, Living Children, Abortions, Stillbirth, Ectopic Pregnancy, Molar Pregnancy, Preterm Birth
Clinical Presentation of COVID-19	Asymptomatic or Symptomatic, details of symptoms, Duration of symptoms, Intervals–symptoms onset to admission, Exposure/contact to diagnosis, Atypical Symptoms, Complications of COVID-19 (ARDS, Consolidation, Heart Failure, Septic Shock, Acute Renal Injury, etc.)
General Physical Examination	BMI, Stability of vitals, Oxygen Saturation at time of Admission, Lowest Oxygen saturation during hospitalization, Date, and method of COVID-19 Testing, Type of sample for COVID-19 Testing, Indications of COVID-19 Testing, X-ray, CT scan, other Laboratory Investigations, Co-infections like Malaria, Dengue, etc
Delivery Details	 Pregnancy Outcomes: Delivered (Singleton/Multifetal), Undelivered, Spontaneous Abortion, Stillbirth, Ectopic Pregnancy, MTP Delivery details: Mode of delivery, Duration of labor, Induction, CS details, Complications Pregnancy Complications: Preeclampsia, Eclampsia, Placenta Previa, Placenta Abruption, Uterine Rupture, Premature Rupture Of Membranes, Oligohydramnios, Polyhydramnios, Antepartum

	Postpartum Hemorrhage, Gestational Hypertension, Gestational Diabetes/ Pregestational Diabetes Mellitus, Preterm Labour, Chorioamnionitis, Fetal Growth Restriction, Congenital Malformation, Hematoma, Surgical Site Infection
Treatment	Antibiotics, Antivirals, Hydroxychloroquine, Steroids, Heparin, High-flow nasal cannula oxygen therapy, NIV, any other treatment and outcomes, Hospital and ICU stay, Blood transfusion, Convalescent Plasma Therapy
Newborn Information	Parameters
Basic demographic and clinical investigations	Date of birth, 5 min APGAR score, Gender, Congenital anomalies, Birth Weight, Feeding Details, NICU admission, Neonatal Compilations, Indications and duration of NICU admission, Vaccination details, Testing for COVID-19, Cord blood testing for COVID-19(if available), Laboratory Investigations, Treatment and outcomes.

405

- 406 APGAR- Appearance, Pulse, Grimace, Activity, and Respiration, CS- Cesarean delivery, MTP-
- 407 Medical Termination of Pregnancy, NIV- Non-Invasive Ventilation

408

409

410 Figure Legends

- 411 **Figure 1:** Flowchart showing details on data collection, quality control, data analysis to be used
- 412 for PregCovid Registry

413

414

